Translational Research in Breast Cancer Patients
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 9814
Special Issue Editor
Interests: general oncology; thoracic cancers; medical education and examination; head and neck cancer; clinical trials design
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Translation is the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public, and observations in the community, public, and clinic into the laboratory. In Breast Cancer patients, at the end of the 19th century, ‘translational scientists’ turned the observation that some breast cancers regressed after menopause into the first effective hormone treatment (oophorectomy) for breast cancer and subsequent pharmacologic interventions along the hormone axis, such as estrogen receptor modulators and antagonists and aromatase inhibitors. At the end of the 20th century, new techniques for observation led to the discovery that the HER2 protein identified a particularly aggressive type of breast cancer, and led to the therapeutic development of Trastuzumab and subsequent HER2-targeted therapies, including small molecules, additional antibodies, and anti-body drug conjugates.
Observations leading to hypotheses, leading to understanding, leading to improved outcomes have been the heart of medicine from the late 1800s and continue today. This Special Issue will highlight some translational aspects of research on the treatment of patients with breast cancer today.
Dr. Andrew G. Robinson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- translational research
- treatment
- patients
- outcomes
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
